An in-depth examination of how FDA's user fee negotiations, "America First" proposals, and Pre-Check Programme are incentivising domestic investment while creating nuanced barriers for CMOs and international manufacturers navigating US market access. These policy shifts extend through 2031–2032 and are fundamentally altering global pharmaceutical investment patterns and manufacturing location decisions.
